| abstract |
The present invention relates to new compounds, in particular, new pyridinone derivatives according to formula (1), which include any of its stereochemically isomeric forms, or a solvate or a pharmaceutically acceptable salt of the compounds, wherein all radicals are defined in the application and in the claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 ("mGluR2"), useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the subtype participates mGluR2 of metabotropic receptors. In particular, said diseases are disorders of the central nervous system selected from the group of anxiety, schizophrenia, migraine, depression and epilepsy. The invention also relates to pharmaceutical compositions and processes for the preparation of such compounds and such compositions, as well as the use of these compounds for the prevention and treatment of the diseases in which mGluR2 participates. |